Head and neck paragangliomas in Norway, importance of genetics, updated diagnostic workup and treatment

Abstract Background Head and neck paragangliomas (HNPG) are rare and predominantly benign tumours, originating from the neuroendocrine paraganglionic system. A considerable proportion of HNPGs are hereditary, depending on the population. Aims/objectives The purpose of this study was to estimate the rate of hereditary HNPGs in a Scandinavian (Norwegian) population, report long-term experience with HNPGs and offer all patients diagnosed an updated follow-up, with emphasis on identifying hereditary HNPGs through genetic screening and multifocality by 18 F-2-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Material and methods Our study was a partly retrospective and partly prospective cohort study. It included patients with HNPG diagnosed at Oslo University Hospital (OUH), Rikshospitalet between 1990 and 2017. The patients underwent genetic testing, 18F-FDG PET/CT and measurement of catecholamines and meta-nephrines in the plasma. All resection specimens and biopsies were subjected to histopathological review. The genetic testing protocol consisted of testing for mutations in the following genes; SDHD, SDHB, SDHC, VHL and RET. Results Sixty-three patients were included in the study with a median age of 49 years (range 12 − 80). Cranial nerve dysfunction was present upon diagnosis in 13%, and 14% had multifocal paraganglioma (PG) disease. Fifty-six patients (89% of all the patients) underwent genetic testing, and 29% of these had a PG related mutation. Seven of the eight patients (88%) with multifocal PGs who underwent genetic testing had a mutation. In two of the patients, the 18F-FDG PET/CT revealed unknown and subclinical multifocality. Conclusions and significance This is the first study with systematic genetic workup and PET/CT imaging in Scandinavia of HNPG patients. The mutation rate was within the lower range reported in the literature with respect to HNPGs. Combining genetic testing and PET/CT imaging in the diagnostic workup of HNPGs is valuable.

[1]  E. Hindié,et al.  European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  S. Woo,et al.  Performance of 68Ga-DOTA–Conjugated Somatostatin Receptor–Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis , 2018, The Journal of Nuclear Medicine.

[3]  Jie Liu,et al.  68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis , 2018, Acta radiologica.

[4]  Michelle D. Williams,et al.  Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics , 2017, Head and Neck Pathology.

[5]  M. Persky,et al.  Treatment of Head and Neck Paragangliomas. , 2016, Cancer control : journal of the Moffitt Cancer Center.

[6]  S. Abu-Ghanem,et al.  Impact of preoperative embolization on the outcomes of carotid body tumor surgery: A meta‐analysis and review of the literature , 2016, Head & neck.

[7]  B. S. Yurrita,et al.  Head and neck paragangliomas: Experience in 126 patients with 162 tumours. , 2015, Acta otorrinolaringologica espanola.

[8]  B. Robinson,et al.  15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5 , 2015, Endocrine-related cancer.

[9]  H. Neumann,et al.  Genetics of hereditary head and neck paragangliomas , 2014, Head & neck.

[10]  W. Mendenhall,et al.  Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy , 2013, Head & neck.

[11]  J. Carrasquillo,et al.  Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. , 2012, Journal of the National Cancer Institute.

[12]  P. Devilee,et al.  Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients , 2011, Clinical endocrinology.

[13]  Herb Chen,et al.  The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.

[14]  H. Neumann,et al.  Malignant Head and Neck Paragangliomas in SDHB Mutation Carriers , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[15]  A. Monabati,et al.  Cytologic Findings in Carotid Body Tumors , 2002, Acta Cytologica.

[16]  W. Rubinstein,et al.  Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas , 2002, Journal of medical genetics.

[17]  L. Karnell,et al.  National Cancer Data Base report on malignant paragangliomas of the head and neck , 2002, Cancer.

[18]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[19]  J. Schipper,et al.  Paragangliomas of the head and neck: diagnosis and treatment , 2004, Familial Cancer.